会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • TRANSDERMAL FORMULATIONS OF LAQUINIMOD
    • LAQUINIMOD的透皮配方
    • US20160038435A1
    • 2016-02-11
    • US14773658
    • 2014-03-13
    • Ralph STEFANHans-Juergen MIKATanja PRIESDirk SCHENKSabine PROHL
    • Ralph STEFANHans-Juergen MIKATanja PRIESDirk SCHENKSabine PROHL
    • A61K9/70A61K47/14A61K47/12A61K31/4704A61K47/10
    • A61K9/7061A61K9/7084A61K31/4704A61K47/10A61K47/12A61K47/14
    • This invention provides a transdermal patch comprising a) a backing layer; b) a liner; c) optionally, a highly porous membrane; and d) a pharmaceutical composition comprising: (i) optionally, a pressure sensitive adhesive in an amount of up to about 95 wt % of the pharmaceutical composition, (ii) laquinimod in an amount of about 0.1-20 wt % of the pharmaceutical composition, and (iii) optionally, one or more permeation enhancers in a total amount of up to about 70 wt % of the pharmaceutical composition. This invention also provides a method for delivering laquinimod across the skin of the subject and for treating a human subject afflicted with a form of multiple sclerosis comprising administering to the skin of the subject a transdermal patch as described herein. This invention further provides a transdermal patch as described herein for use in treating a human subject afflicted with a form of multiple sclerosis.
    • 本发明提供一种透皮贴剂,其包含:a)背衬层; b)衬垫; c)任选地,高度多孔的膜; 和d)药物组合物,其包含:(i)任选地,所述药物组合物的至多约95重量%的量的压敏粘合剂,(ii)所述药物组合物的约0.1-20重量%的拉喹莫德 ,和(iii)任选的一种或多种渗透促进剂,其总量高达药物组合物的约70重量%。 本发明还提供了一种递送角质层跨越受试者皮肤并用于治疗患有多发性硬化症形式的人类受试者的方法,包括向受试者的皮肤施用如本文所述的透皮贴片。 本发明还提供了本文所述的用于治疗患有多发性硬化症形式的人类受试者的透皮贴剂。